Business, energy, technology, markets and global industry news from Business News Today

guselkumab

PharmaDeviceNews guselkumab
Pharma & Biotech

Can Johnson & Johnson’s oral Icotyde compete with biologics in psoriatic arthritis?

Icotyde achieved 58% ACR20 in Phase 3 psoriatic arthritis, but the 400 mg dose added no benefit. Can Johnson & Johnson challenge biologics?

Read More
Pharma & Biotech

Skyrizi reaches 73.1% remission in a Crohn’s subgroup. Can AbbVie secure a new FDA dosing option?

AbbVie reports new Skyrizi and Rinvoq Crohn's disease data, including Phase III remission results and long-term findings. Examine the evidence.

Read More
Representative image showing a clinician reviewing joint health with a patient, reflecting Johnson & Johnson’s Tremfya FDA label expansion for structural joint damage inhibition in active psoriatic arthritis.
Pharma & Biotech

Can Tremfya turn radiographic evidence into a commercial advantage for Johnson & Johnson?

Find out how Johnson & Johnson’s Tremfya label expansion could reshape IL-23 competition in psoriatic arthritis care.

Read More
Johnson & Johnson strengthens its ulcerative colitis position with extended guselkumab outcomes
Pharma & Biotech

Johnson & Johnson’s three-year TREMFYA data sharpen the durability debate in ulcerative colitis care

Johnson & Johnson’s three-year TREMFYA data highlight why sustained remission is redefining ulcerative colitis treatment decisions. Read the analysis.

Read More